Low dose recombinant interferon alfa treatment for classic... of interferon alfa are used to treat Kaposi's sarcoma in... Following low-dose recombinant interferon alfa treatment for lymphoma...
Long-term experience with low-dose interferon-&agr; and PUVA... high-dose Interferon-&agr; and psoralen plus ultraviolet A... Interferon treatment of cutaneous T‐cell lymphoma. European...
Abstract ; Objective: To compare efficacy of interferon β-1a, 22 μg or 44 μg weekly, with placebo in relapsing MS. Background: Uncertainty exists concerning the optimal dose regimen for interferon β in relapsing-remitting MS. Many patients and physicians prefer the convenience and lesser side effects of an injection given once weekly (qw) as opposed to three times weekly. Pharmacokinetic data and information on biologic markers suggest that this frequency may be suboptimal. Methods: Randomized, double-blind study of interferon β-1a 22 μg, ...
High versus standard doses interferon-alpha in the treatment... The dose-effect, tolerability and durability of interferon... alpha interferon therapy in chronic hepatitis C J Hepatol 1998 29...
Abstract ; Background : Depression commonly complicates treatment with the cytokine interferon alfa-2b. Laboratory animals pretreated with antidepressants have less severe depression-like symptoms after the administration of a cytokine. We sought to determine whether a similar strategy would be effective in humans. Methods : In a double-blind study of 40 patients with malignant melanoma who were eligible for high-dose interferon alfa therapy, we randomly assigned 20 patients to receive the antidepressant paroxetine and 20 to receive placebo. Th ...
Backed by over 100 research and clinical studies, we developed Veldona, a low-dose oral interferon-alpha (IFN-α) formulation to boost the human body’s frontline defenses against disease...
Abstract The type I interferon response protects cells... of interferon-stimulated genes (ISGs). Although hundreds of ISGs... I interferon doses. Mechanistic studies uncovered a common...
A randomized trial of maintenance interferon following high... As the cytokine interferon alpha has been ... 참고문헌 (33)... 29 13 2 1986 Interferon alfa‐2b in the treatment chronic...
A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in... AI-Helper Interferon-α (IFN-α) has significantly prolonged survival in chronic myeloid...
저자, Verdegaal E ; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands [email protected]. van der Kooij MK ; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands. Visser M ; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands. van der Minne C ; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands. de Bruin L ; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands. Meij P ; GMP Facility Leiden, Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands. Terwisscha van Scheltinga A ; GMP Facility Leiden, Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands. Welters MJ ; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands. Santegoets S ; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands. de Miranda N ; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. Roozen I ; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands. Liefers GJ ; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. Kapiteijn E ; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands. van der Burg SH ; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands. ; Content Provider, MEDLINE Ultimate ; 초록, Background: Adoptive cell therapy (ACT) with tumor-reactive T cells has shown consistent clinical efficacy. We evaluated the response to ACT in combination with interferon alpha (IFNa) preconditioning in patients with stage IV metastatic melanoma, most of which were progressive on cytotoxic T-lymphocyte-associated protein 4 and/or programmed cell death protein 1 checkpoint blockade therapy. Methods: Thirty-four patients were treated with ex vivo expanded tumor reactive T cells, derived from mixed lymphocyte autologous tumor cultures, or with autologous tumor-infiltrating lymphocytes and evaluated for clinical response. Clinical and immunological parameters associated with response were also evaluated. Results: Best overall response defined as clinical benefit, comprising either complete response, partial response or stable disease >6 months, was observed in 29% of the patients. Forty-three per cent of the 14 immunotherapy-naïve patients and 20% of the 20 patients progressive on prior immunotherapy benefited from ACT. The overall survival (OS) was 90% versus 28.6% at 1 year and 46.7% versus 0% at 3 years follow-up, of responder and non-responder patients, respectively. Median OS was 36 versus 7 months, respectively. IFNa pretreatment resulted in leukopenia, neutropenia and lymphopenia, which was sustained during the treatment in clinical responders and associated with response. Differences in antigen specificity, but not in phenotype, cytokine profile or CD8+ T cell number of the ACT products correlated with clinical response. Cross-reactivity of the ACT products to one or more allogeneic human leukocyte antigen-matched melanoma cell lines was associated with short OS after treatment while the ACT products of very long-term survivors showed no cross-reactivity but recognized patient-specific neoantigens. Conclusion: This study demonstrates that ACT in combination with a mild IFNa preconditioning regimen can induce clinical benefit even in immunotherapy pretreated patients, although with lower success than in immunotherapy-naïve patients. ACT products comprising neoantigen reactivity may be more effective. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) ; Publication Type, Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't